Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia

82Citations
Citations of this article
49Readers
Mendeley users who have this article in their library.

Abstract

Tardive dyskinesia (TD) is a disabling neurological side effect associated with long-term treatment with typical antipsychotics. Family studies and animal models lend evidence for hereditary predisposition to TD. The newer atypical antipsychotics pose a minimal risk for TD which is in part attributed to their ability to block the serotonin-2A (5-HT2A) receptor. 5-HT2A receptors were also identified in the basal ganglia; a brain region that plays a critical role in antipsychotic-induced movement disorders. We tested the significance of variation in the 5-HT2A receptor gene (HTR2A) in relation to the TD phenotype. Three polymorphisms in HTR2A, one silent (C102T), one that alters the amino acid sequence (his452tyr) and one in the promoter region (A-1437G) were investigated in 136 patients refractory or intolerant to treatment with typical antipsychotics and with a DSM-IIIR diagnosis of schizophrenia. We did not find any significant difference in allele, genotype or haplotype frequencies of polymorphisms in HTR2A among patients with or without TD (P>0.05). Further analysis using the ANCOVA statistic with a continuous measure of the TD phenotype (Abnormal Involuntary Movement Scale (AIMS) score) found that the AIMS scores were not significantly influenced by HTR2A polymorphisms, despite controlling for potential confounders such as age, gender and ethnicity (P>0.05). Theoretically, central serotonergic function can be subject to genetic control at various other mechanistic levels including the rate of serotonin synthesis (tryptophane hydroxylase gene), release, reuptake (serotonin transporter gene) and degradation (monoamine oxidase gene). Analyses of these other serotonergic genes are indicated. In summary, polymorphisms in HTR2A do not appear to influence the risk for TD. Further studies evaluating in tandem multiple candidate genes relevant for the serotonergic system are warranted to dissect the genetic basis of the complex TD phenotype.

References Powered by Scopus

A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies

2040Citations
N/AReaders
Get full text

Research Diagnoses for Tardive Dyskinesia

936Citations
N/AReaders
Get full text

The role of serotonin in antipsychotic drug action

667Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Pharmacogenetics of antidepressants and antipsychotics: The contribution of allelic variations to the phenotype of drug response

668Citations
N/AReaders
Get full text

Pharmacogenetics and pharmacogenomics of schizophrenia: A review of last decade of research

308Citations
N/AReaders
Get full text

Pharmacogenetics of tardive dyskinesia: Combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism

249Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Basile, V. S., Ozdemir, V., Masellis, M., Meltzer, H. Y., Lieberman, J. A., Potkin, S. G., … Kennedy, J. L. (2001). Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia. Molecular Psychiatry, 6(2), 230–234. https://doi.org/10.1038/sj.mp.4000847

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 15

54%

Researcher 7

25%

Professor / Associate Prof. 6

21%

Readers' Discipline

Tooltip

Medicine and Dentistry 12

43%

Agricultural and Biological Sciences 9

32%

Psychology 4

14%

Pharmacology, Toxicology and Pharmaceut... 3

11%

Save time finding and organizing research with Mendeley

Sign up for free